Summary: In a small single-centre randomised trial of 61 adults with obesity and newly diagnosed prediabetes or type 2 diabetes, adding a high-protein diet and moderate exercise to weight-lowering hypoglycaemic medication produced a 12-month diabetes-subgroup remission rate of 86.67% versus 16.67% with standard care (P<0.001), alongside a mean weight change of -19.29 kg versus -1.52 kg (net difference -17.77 kg; 95% CI -22.90 to -12.64; P<0.001). The effect is large but the sample is small and the design open-label.
PICO Summary
| Element | Detail |
|---|---|
| Population | 61 adults with obesity and newly diagnosed prediabetes or type 2 diabetes; single-centre randomised controlled trial, China (ChiCTR2100044305); 60 of 61 (98.4%) completed 12-month follow-up. |
| Intervention | Intensive group: conventional hypoglycaemic medication (agents with a weight-loss effect) plus a high-protein diet and moderate exercise for 12 months. |
| Comparison | Standard group: conventional medication plus lifestyle guidance for 12 months. |
| Outcome | Diabetes subgroup remission: 86.67% (intensive) vs 16.67% (standard), P<0.001. Prediabetes subgroup return to normoglycaemia: 73.33% vs 7.69%. Mean weight change: -19.29 kg (95% CI -22.95 to -15.63) vs -1.52 kg (95% CI -5.12 to 2.07); net between-group difference -17.77 kg (95% CI -22.90 to -12.64), P<0.001. Body-fat percentage, visceral fat area, and hepatic controlled attenuation parameter fell significantly in the intensive group (P<0.001). No 95% CI, absolute risk reduction, or number needed to treat was reported for the remission endpoint. |
High-protein diet + exercise for T2D remission
RCT · obesity + type 2 diabetes · 12 months
Adding a high-protein diet and moderate exercise to weight-lowering medication produced an 86.7% vs 16.7% diabetes-remission rate at 12 months, but the trial is small and open-label.
Expert Commentary
This trial reports a striking signal: layering a high-protein diet and structured moderate exercise onto weight-lowering hypoglycaemic medication was associated with diabetes remission in roughly six of seven participants and almost 18 kg more weight loss than standard care over 12 months. The weight outcome is reported with a tight confidence interval and is biologically coherent, since remission in early type 2 diabetes tracks closely with the magnitude of weight loss. The verdict, however, must stay cautious. This is a single-centre study of only 61 people, and the headline remission figures rest on very small subgroups, so the percentages are imprecise and no confidence interval, absolute risk reduction, or number needed to treat is given for that endpoint. The principal limitation is the open-label design with an unblinded behavioural intervention, which invites performance and ascertainment bias and tends to inflate effect sizes; the implausibly large remission gap should be read in that light. No industry sponsorship is declared in the abstract. Can I use this with my patients? Not yet as a defined protocol, though it reinforces the existing case for aggressive, supervised weight loss in motivated adults with recent-onset disease and obesity. Larger, multicentre, longer-term trials with prespecified remission definitions and durability data are needed before this bundle is recommended as standard care.
References
Zhang S, Wang Y, Wang X, Leng M, Liu R, Li Z, et al. Effect of hypoglycemic agents with weight loss effect plus a high protein diet and moderate exercise on diabetes remission in adults with obesity and type 2 diabetes: a randomized controlled trial. BMC Medicine. 2025;23(1):270. doi:10.1186/s12916-025-04072-4